Newron Pharmaceuticals SPA
Newron Pharmaceuticals SPA/ IT0004147952 /
NWPHF
24.06.2024 15:30:02
|
Изменение
-
|
Объем сделки |
Бид- |
Предложение- |
Рыночная капитализация |
Дивидендная доходность |
Коэффициент Цена/Доход |
12.0000USD
|
-
|
100 Оборот: 1,200 |
-Величина цены спроса: - |
-Величина цены предложения: - |
170.74 млнUSD |
- |
- |
Описание деятельности
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil and Colombia and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights from Zambon for the US. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
Правление & Наблюдательный совет
Исполнительный директор |
Stefan Weber |
Правление |
Ravi Anand, Laura Faravelli, Roberto Galli, Dennis Dionne, Filippo Moriggia |
Наблюдательный совет |
Dr. Ulrich Köstlin, Patrick Langlois, Luca Benatti, Gillian Dines, Stefan Weber |
Данные компании
Имя: |
Newron Pharmaceuticals S.p.A. |
Адрес: |
Newron Pharmaceuticals SpA, via Antonio Meucci 3,I-20091 Bresso (Mi) |
Телефон: |
+39-02-610-3461 |
Факс: |
+39-02-610-34654 |
E-mail: |
info@newron.com
|
Интернет: |
www.newron.com/en |
Индустрия: |
Healthcare |
Сектор: |
Pharmaceutical Industry |
Подсектор: |
Pharmaceuticals |
Конец финансового года: |
31.12 |
Акции в свободном обращении: |
91.91% |
Дата IPO: |
- |
Связи с инвесторами
Имя: |
Stefan Weber |
IR телефон: |
+39-02-610-34609 |
IR-факс: |
- |
IR e-mail: |
ir@newron.com
|